Deutsche Bank Ag\ Aurinia Pharmaceuticals Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 92,294 shares of AUPH stock, worth $749,427. This represents 0.0% of its overall portfolio holdings.

Number of Shares

92,294

Previous 72,300 27.65%

Holding current value

$749,427

Previous $412,000 64.08%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$5.32 - $7.33 $106,368 - $146,556	19,994 Added 27.65%	92,294 $676,000
Q2 2024 Aug 14, 2024	SELL	$4.81 - $5.78 $45,218 - $54,337	-9,401 Reduced 11.51%	72,300 $412,000
Q1 2024 May 15, 2024	BUY	$4.93 - $9.31 $32,572 - $61,511	6,607 Added 8.8%	81,701 $409,000
Q4 2023 Feb 14, 2024	SELL	$7.13 - $9.49 $2,524 - $3,359	-354 Reduced 0.47%	75,094 $675,000
Q3 2023 Nov 09, 2023	BUY	$7.77 - $12.27 $6,068 - $9,582	781 Added 1.05%	75,448 $586,000
Q2 2023 Aug 14, 2023	SELL	$8.96 - $11.69 $247,287 - $322,632	-27,599 Reduced 26.99%	74,667 $722,000
Q1 2023 May 15, 2023	BUY	$5.94 - $11.27 $128,476 - $243,758	21,629 Added 26.82%	102,266 $1.12 Million
Q4 2022 Feb 13, 2023	BUY	$4.11 - $8.14 $82,191 - $162,783	19,998 Added 32.98%	80,637 $348,000
Q3 2022 Nov 14, 2022	SELL	$6.66 - $12.39 $116,809 - $217,308	-17,539 Reduced 22.43%	60,639 $456,000
Q2 2022 Aug 11, 2022	BUY	$8.95 - $12.8 $621,407 - $888,716	69,431 Added 793.77%	78,178 $786,000
Q1 2022 May 13, 2022	BUY	$10.05 - $22.48 $5,648 - $12,633	562 Added 6.87%	8,747 $108,000
Q4 2021 Feb 11, 2022	BUY	$17.78 - $33.08 $13,655 - $25,405	768 Added 10.35%	8,185 $187,000
Q3 2021 Nov 04, 2021	SELL	$10.93 - $23.55 $1.7 Million - $3.66 Million	-155,262 Reduced 95.44%	7,417 $164,000
Q2 2021 Aug 11, 2021	BUY	$10.0 - $14.52 $1.49 Million - $2.16 Million	148,646 Added 1059.26%	162,679 $2.11 Million
Q1 2021 May 13, 2021	BUY	$12.3 - $18.73 $99,261 - $151,151	8,070 Added 135.33%	14,033 $182,000
Q4 2020 Feb 16, 2021	SELL	$12.94 - $16.05 $91,201 - $113,120	-7,048 Reduced 54.17%	5,963 $82,000
Q3 2020 Nov 12, 2020	BUY	$13.19 - $16.66 $102,921 - $129,997	7,803 Added 149.83%	13,011 $192,000
Q2 2020 Aug 13, 2020	SELL	$14.12 - $18.33 $12,708 - $16,497	-900 Reduced 14.73%	5,208 $85,000
Q1 2020 May 14, 2020	SELL	$11.34 - $21.46 $155,913 - $295,053	-13,749 Reduced 69.24%	6,108 $89,000
Q4 2019 Feb 14, 2020	BUY	$3.88 - $21.42 $77,045 - $425,336	19,857 New	19,857 $402,000
Q3 2019 Nov 14, 2019	SELL	$5.34 - $6.59 $8,656 - $10,682	-1,621 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$6.05 - $6.75 $1.02 Million - $1.14 Million	-168,834 Reduced 99.05%	1,621 $10,000
Q1 2019 May 15, 2019	BUY	$6.06 - $7.64 $631,785 - $796,508	104,255 Added 157.48%	170,455 $1.11 Million
Q4 2018 Feb 14, 2019	BUY	$5.08 - $6.83 $208,701 - $280,596	41,083 Added 163.57%	66,200 $451,000
Q3 2018 Dec 21, 2021	BUY	$5.27 - $6.64 $64,383 - $81,120	12,217 Added 94.71%	25,117 $167,000
Q3 2018 Nov 14, 2018	SELL	$5.27 - $6.64 $87,065 - $109,699	-16,521 Reduced 56.15%	12,900 $85,000
Q2 2018 Apr 21, 2020	BUY	$5.06 - $6.36 $78,096 - $98,160	15,434 Added 110.35%	29,421 $166,000
Q2 2018 Aug 14, 2018	SELL	$5.06 - $6.36 $120,893 - $151,953	-23,892 Reduced 63.07%	13,987 $78,000
Q1 2018 Oct 18, 2019	BUY	$4.85 - $5.99 $71,411 - $88,196	14,724 Added 63.59%	37,879 $196,000
Q1 2018 May 15, 2018	BUY	$4.85 - $5.99 $66,333 - $81,925	13,677 Added 144.3%	23,155 $119,000
Q4 2017 Feb 14, 2018	SELL	$4.53 - $7.09 $200,108 - $313,193	-44,174 Reduced 82.33%	9,478 $42,000
Q3 2017 Nov 14, 2017	BUY	$5.71 - $6.9 $306,352 - $370,198	53,652	53,652 $335,000

Others Institutions Holding AUPH

# of Institutions

209

Shares Held

58.7M

Call Options Held

1.14M

Put Options Held

1.51M

View Full List

About Aurinia Pharmaceuticals Inc.

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.15B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

More about AUPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account